Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response

Liver International

Volumn 33, Issue 7, 2013, Pages 999-1007

  Lubega, Samali ^a   Agbim, Uchenna ^a   Surjadi, Miranda ^a   Mahoney, Megan ^a   Khalili, Mandana ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Health disparity; Hepatitis C education; Hepatitis C knowledge; Hepatitis C treatment; Provider survey; Vulnerable populations

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PATIENT EDUCATION; PRIMARY MEDICAL CARE; TREATMENT RESPONSE; VIRUS LOAD;

HEALTH DISPARITY; HEPATITIS C EDUCATION; HEPATITIS C KNOWLEDGE; HEPATITIS C TREATMENT; PROVIDER SURVEY; VULNERABLE POPULATIONS;

ADULT; AGE FACTORS; CONTINENTAL POPULATION GROUPS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT EDUCATION AS TOPIC; PHYSICIANS, PRIMARY CARE; RETROSPECTIVE STUDIES; SAN FRANCISCO; SEX FACTORS; TIME-TO-TREATMENT; VIRAL LOAD;

EID: 84880174906     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12150     Document Type: Article

References (35)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
2. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
3. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-5.
4. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14-28.
5. Canfield KM, Smyth E, Batki SL. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse 2010; 45: 496-514.
6. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales Australia. J Viral Hepatitis 2011; 18: e104-16.
7. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77: 81-6.
8. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on 'Chronic viral hepatitis-strategies to improve effectiveness of screening and treatment'. Hepatology 2012; 55: 307-15.
9. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-8.
10. Mitchell AE, Colvin HM. Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-33.
11. Guy J, Yee HF Jr. Health disparities in liver disease: time to take notice and take action. Hepatology 2009; 50: 309-13.
12. Beste LA, Straits-Troster K, Zickmund S, et al. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 275-82.
13. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011; 56: 213-9.
14. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28: 181-7.
15. Gupta K, Romney D, Briggs M, Benker K. Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals. J Community Health 2007; 32: 221-30.
16. Chen AH, Yee HF Jr. Improving the primary care-specialty care interface: getting from here to there. Arch Intern Med 2009; 169: 1024-6.
17. Bindman AB, Chen A, Fraser JS, Yee HF Jr, Ofman D. Healthcare reform with a safety net: lessons from San Francisco. Am J Manag Care 2009; 15: 747-50.
18. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
19. Balfour L, Cooper C, Tasca GA, et al. Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. Can J Public Health. Revue canadienne de sante publique 2004; 95: 272-7.
20. Clark EC, Yawn BP, Galliher JM, Temte JL, Hickner J. Hepatitis C identification and management by family physicians. Fam Med 2005; 37: 644-9.
21. Cox J, Graves L, Marks E, et al. Knowledge, attitudes and behaviours associated with the provision of hepatitis C care by Canadian family physicians. J Viral Hepatitis 2011; 18: e332-40.
22. Leverence RR, Williams RL, Pace W, et al. Context of clinical care: the case of hepatitis C in underserved communities-a report from the Primary Care Multiethnic Network (PRIME Net) Consortium. J Am Board Fam Med 2009; 22: 638-46.
23. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepatitis 2001; 8: 377-83.
24. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C? Am J Med 2005; 118: 1387-91.
25. Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy 2005; 25: 1230-41.
26. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32(Suppl 1): 151-6.
27. Cacoub P, Ouzan D, Melin P, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008; 14: 6195-203.
28. Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 2010; 33: 368-73.
29. Larrey D, Salse A, Ribard D, et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-alpha2a and ribavirin. Clin Gastroenterol Hepatol 2011; 9: 781-5.
30. Lo Re V IIIrd, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48:186-93.
31. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010; 30: 240-50.
32. Evon DM, Esserman DA, Ramcharran D, Bonner JE, Fried MW. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res 2011; 71: 349-56.
33. Osilla KC, Wagner G, Garnett J, et al. Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment. AIDS Patient Care STDs 2011; 25: 533-8.
34. Wagner G, Ryan G, Osilla KC, et al. Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection. AIDS Patient Care STDs 2009; 23: 715-25.
35. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepatitis 2010; 17: 839-44.